1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pancreatic Cancer: Disease and Pipeline Analysis

Pancreatic Cancer: Disease and Pipeline Analysis

  • March 2013
  • -
  • Industry Standard Research
  • -
  • 67 pages

The pancreas is the 10th most common site of new cancers but is the 4th leading cause of cancer death, largely due the difficulties associated with diagnosing the disease in its early stages. As a consequence, over 80% of patients present with regional spread or distant disease at the time of diagnosis (Stage III or Stage IV) and are unsuitable for surgical resection. Survival rates from the disease are among the lowest for any type of cancer with a median survival time of 4-6 months from diagnosis, a 1-year survival rate of 26% and a 5-year survival rate of only 6%. Following curative resection, median survival time increases to between 12 and 19 months.

In a market with few available therapies that exhibit limited effectiveness and a disease class still classified as “rare”, poor survival rates and lack of viable treatment options remain compelling reasons to develop new “Orphan” therapies to address this large unmet need.

What you will learn in this report:

• Information on over sixty potential new therapies in active development
• Incidence rate of pancreatic cancer for each of the major and emerging global markets
• Drug approval dynamics by country
• Trial and Recruitment environment
• Regulatory environment
• Competitive product landscape
• Pricing and reimbursement environment

How you can use this report:

• Optimize your product’s global development and commercial strategies
• Benchmark trial length and number of patients (by Phase)
• Identify drug candidates for partnering strategies
• Evaluate your pipeline against products currently in development
• Identify the most effectives market entry strategies

Valuable for:

1. Brand Managers
2. Medical Directors
3. Portfolio Managers
4. Executive Suite

Table Of Contents

Pancreatic Cancer: Disease and Pipeline Analysis
Table of Contents

Copyright and Usage Guidelines 6
Table of Abbreviations 7
Table of Definitions 8
Chapter 1.Pancreatic Cancer Overview 9
Chapter 2.Commercial Rationale 11
High Unmet Need and Limited Available Therapies 12
Increasing Pancreatic Cancer Incidence 16
Orphan Disease Status 17
Active Drug Development Field 18
Chapter 3.Environmental Analysis 19
Disease Epidemiology 19
Major Markets Environmental Analysis 21
Emerging Markets Environmental Analysis (BRICK) 25
Additional Countries 29
Chapter 4.Clinical Development Pipeline 31
RandD Trends in the Treatment of Pancreatic Cancer 31
Late Phase Pancreatic Cancer Development Pipeline 34
Masitinib, AB Science 35
GV-1001, KAEL-GemVax 37
Abraxane, Celgene Corporation 38
HyperAcute Pancreas, NewLink Genetics 39
MM-398, Merrimack Pharma 40
Polyclonal Antibody Stimulator, Cancer Advances Inc 41
Estybon (rigositib), OncoNova Therapeutics 42
TH302, Merck KGaA and Threshold Pharma 43
Early Phase Pancreatic Cancer Development Pipeline 44
Recent Clinical Development Failures 48
Chapter 5.Clinical Trial Environment 49
Geographic summary 53
Bibliography 66
About ISR 67



List of Tables

Table 1.Major Pancreatic Cancer Drug Treatments 13
Table 2.Pancreatic Cancer - Major Markets Patient Population and Product Environment 21
Table 3.Developed Markets Forecast Future Pancreatic Cancer Incidence 24
Table 4.Pancreatic Cancer - Emerging Markets Patient Population and Product Environment 25
Table 5.Emerging Markets Forecast Future Pancreatic Cancer Incidence 28
Table 6.The Late Phase Pancreatic Cancer Pipeline 34
Table 7.Overview of Masitinib 36
Table 8.Overview of GV-1001 37
Table 9.Overview of Abraxane 38
Table 10.Overview of HyperAcute Pancreas 39
Table 11.Overview of MM-398 40
Table 12.Overview of Polyclonal Antibody Stimulator 41
Table 13.Overview of Rigosirtib 42
Table 14.Overview of TH302 43
Table 15.Early Phase Pancreatic Cancer Development Pipeline: Immunotherapy 44
Table 16.Early Phase Pancreatic Cancer Pipeline: Signaling Pathway Inhibitors 44
Table 17.Early Phase Pancreatic Cancer Pipeline: Tumour Microenvironment 46
Table 18.Early Phase Pancreatic Cancer Pipeline: Chemotherapeutic Agents 47
Table 19.Pancreatic Cancer Trials by Development Phase: All Sponsors 50
Table 20.Ongoing, Industry-Sponsored Pancreatic Cancer Trials 51
Table 21.Recently Completed, Industry-Sponsored Pancreatic Cancer Trials 52













List of Figures

Figure 1.Global Map of Percentage of Tobacco Use Among Adults (2005) 16
Figure 2.Global Map of per Capita Adult Alcohol Consumption (Pure Alcohol, litres) 17
Figure 3.Countries with the Highest Populations of Pancreatic Cancer Patients 29
Figure 4.Countries with Highest Age Standardized Rate of Pancreatic Cancer 30
Figure 5.Schematic of the Major Intracellular Signaling Pathways and
Drugs which Act on Them ………………………………………………………………………… 33


View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Pancreatic Cancer - Market Insights, Epidemiology and Market  Forecast-2023

Pancreatic Cancer - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Pancreatic Cancer - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others), By Region (North America, Europe, Asia Pacific, Latin America And MEA), And Segment Forecasts, 2014 - 2025

Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others), By Region (North America, Europe, Asia Pacific, Latin America And MEA), And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • February 2017
  • by Grand View Research

The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and ...

Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

Global Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by Type of Cancer and Geography (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The global pancreatic cancer market is expected to grow modestly from USD 1,730 million in 2015, growing at a CAGR of 10-17%. Globally, pancreatic cancer is the 12th most common cancer in men and 11th ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

OTC Markets in the US

  • March 2017
    10 pages
  • Pancreatic Canc...  

    Vitamin  

  • United States  

View report >

Milk Industry

  • March 2017
    12 pages
  • Milk  

View report >

Related Market Segments :

Pancreatic Cancer

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.